Patents Examined by Taina D Matos Negron
-
Patent number: 8940757Abstract: The present invention relates to Prasugrel or a pharmaceutically acceptable salt thereof, compositions containing said active ingredient as well as pharmaceutical compositions containing said active ingredient or a composition containing said active ingredient. The present invention further relates to methods for the preparation of the novel compositions.Type: GrantFiled: February 10, 2011Date of Patent: January 27, 2015Assignee: ratiopharm GmbHInventors: Sandra Brueck, Jana Paetz
-
Patent number: 8937176Abstract: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.Type: GrantFiled: December 10, 2012Date of Patent: January 20, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Klaus Rudolf, Daniel Bischoff, Georg Dahmann, Matthias Grauert, Raimund Kuelzer
-
Patent number: 8937081Abstract: A composition for increasing the bioavailability of a statin active pharmaceutical ingredient (“API”) in humans and animals, wherein that composition includes a statin API selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.Type: GrantFiled: December 12, 2012Date of Patent: January 20, 2015Assignee: PruGen IP Holdings, Inc.Inventor: Bhiku G. Patel
-
Patent number: 8927586Abstract: The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.Type: GrantFiled: February 28, 2013Date of Patent: January 6, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: John Q. Trojanowski, Virginia M. Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huym, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli, Sugiyama Shimpei, Xiaozhao Wang
-
Patent number: 8927607Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: GrantFiled: August 22, 2013Date of Patent: January 6, 2015Assignee: Hikma Pharmaceuticals LLCInventor: Murray Ducharme
-
Patent number: 8927550Abstract: Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).Type: GrantFiled: October 21, 2010Date of Patent: January 6, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Brian Nicholas Cook, Daniel Kuzmich
-
Patent number: 8916545Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: GrantFiled: August 3, 2012Date of Patent: December 23, 2014Assignee: Neonc Technologies Inc.Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
-
Patent number: 8907103Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.Type: GrantFiled: August 13, 2009Date of Patent: December 9, 2014Assignee: Metabasis Therapeutics, Inc.Inventors: Jorge E. Gomez-Galeno, Scott J. Hecker, Qun Dang, Mali Venkat Reddy, Zhili Sun, Matthew P. Grote, Thanh Huu Nguyen, Robert Huerta Lemus, Haiqing Li
-
Patent number: 8895611Abstract: The cytotoxic compounds are gold(III) complexes of the type [(diaminocyclohexane)AuCl2]Cl, derived from sodium tetrachloroaurate(III) dihydrate NaAuCl4.2H2O. Specifically, the cytotoxic compounds are gold complexes of isomers of 1,2-diaminocyclohexane, namely cis-(±)-1,2-(diaminocyclohexane)AuCl3, trans-(±)-1,2-(diaminocyclohexane)AuCl3 and S,S-(+)-1,2-(diaminocyclohexane)AuCl3. In order to treat cancer cells in a patient, such as human prostate cancer cells or human gastric cancer cells, an effective amount of the isomer of 1,2-(diaminocyclohexane)AuCl3 is administered to the cancer cells in the patient. The isomer of 1,2-(diaminocyclohexane)AuCl3 is preferably administered with a concentration ranging between about 10 ?M and 20 ?M.Type: GrantFiled: July 17, 2013Date of Patent: November 25, 2014Assignees: King Fahd University of Petroleum and Minerals, King Abdulaziz City for Science and TechnologyInventors: Anvarhusein Abdulkadir Isab, Mohammed Ismail Mohammed Wazeer, Said Salman Al-Jaroudi, Saleh Abdulaziz Altuwaijri
-
Patent number: 8871799Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.Type: GrantFiled: April 20, 2011Date of Patent: October 28, 2014Assignee: Kineta, Inc.Inventors: Shawn P. Iadonato, Kristin Bedard
-
Patent number: 8809309Abstract: Disclosed is the use of 5?-androstane(alkyl)-3?,5,6?-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.Type: GrantFiled: July 8, 2011Date of Patent: August 19, 2014Assignee: Guangzhou Cellprotek Pharmaceutical Ltd.Inventors: Guangmei Yan, Haiyan Hu, Tiandong Leng, Hanfei Sang, Jingxia Zhang, Pengxin Qiu, Shujia Zhou, Jiesi Chen, Xiuhua You
-
Patent number: 8778941Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.Type: GrantFiled: June 21, 2012Date of Patent: July 15, 2014Assignee: AMGEN Inc.Inventors: James Brown, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Qingyian Liu, Holger Monenschein, Thomas T. Nguyen, Nobuko Nishimura, Wenge Zhong
-
Patent number: 8772349Abstract: Cannabinoid quinone derivatives. The present invention refers to cannabinoid quinone derivatives to be used as medicaments, particularly as PPAR gamma (PPARg) agonists for treating diseases which etiology is based on an impaired PPARg function as transcription factor i.e. PPARg-related diseases.Type: GrantFiled: March 26, 2010Date of Patent: July 8, 2014Assignee: Vivacell Biotechnology Espana, S.L.Inventors: Eduardo Muñoz Blanco, Giovanni Appendino, María Luz Bellido Cabello De Alba
-
Patent number: 8772510Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used in the treatment of CNS disorders such as schizophrenia, Alzheimer's disease, and Parkinson's disease.Type: GrantFiled: August 30, 2012Date of Patent: July 8, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Stephan Bachmann, Alexander Flohr, Katrin Groebke Zbinden, Matthias Koerner, Bernd Kuhn, Jens-Uwe Peters, Markus Rudolph
-
Patent number: 8748496Abstract: The present disclosure relates to compositions and methods for reducing uric acid levels in a individual in need thereof. The present disclosure further relates to the treatment of hyperuricemia and diseases associated with high uric acid levels in mammals using scyllo-inositol.Type: GrantFiled: September 15, 2009Date of Patent: June 10, 2014Assignee: Elan Pharmaceuticals, Inc.Inventor: Jesse M. Cedarbaum
-
Patent number: 8685959Abstract: Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.Type: GrantFiled: November 30, 2012Date of Patent: April 1, 2014Assignee: ChemoCentryx, Inc.Inventors: Manmohan Reddy Leleti, Yandong Li, Venkat Reddy Mali, Jay Powers, Ju Yang
-
Patent number: 8614208Abstract: The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.Type: GrantFiled: August 25, 2010Date of Patent: December 24, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Hiroshi Banno, Toshio Tanaka, Satoshi Sasaki
-
Patent number: 8609661Abstract: Provided herein are pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity. The compounds, and compositions comprising the compounds, described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, polycystic kidney disease. The compounds may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.Type: GrantFiled: August 10, 2010Date of Patent: December 17, 2013Assignee: The Regents of the University of CaliforniaInventors: Alan S. Verkman, Lukmanee Tradtrantip
-
Patent number: 8604028Abstract: This invention relates to novel 4-(furo[3,2-c]pyridin-2-yl)-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.Type: GrantFiled: November 15, 2010Date of Patent: December 10, 2013Assignee: Bayer Intellectual Property GmbHInventors: Martin Michels, Hans Briem, Alexandros Vakalopoulos, Katja Zimmermann, Nicole Teusch
-
Patent number: 8592392Abstract: A method for optimizing the health of humans according to their age and sex is disclosed wherein the method comprises administering to said humans a daily dose of a multiple antioxidant micronutrient composition comprising vitamin A (palmitate), beta-carotene (from natural d. salina), vitamin C (calcium ascorbate), vitamin D-3 (cholecalciferol), natural source vitamin E including both d-alpha tocopherol and d-alpha tocopheryl acid succinate, thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid (folacin), d-biotin, selenium (l-seleno methionine), chromium picolinate, zinc glycinate, calcium citrate, and magnesium citrate. For persons over the age of about 51, the composition preferably further comprises one or more of co-enzyme Q10, N-acetyl cysteine, and alpha lipoic acid. Preferably, also, vitamin D is added for women over the age of about 36.Type: GrantFiled: January 11, 2005Date of Patent: November 26, 2013Assignee: Premier Micronutrient CorporationInventors: Kedar N Prasad, Gerald M Haase